Search

Displaying results 4781 - 4790 of 10000 in total
  1. Drug

    GSK-239512

    go.drugbank.com/drugs/DB15120
    Investigational

    GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).

  2. Drug

    Fosmanogepix

    go.drugbank.com/drugs/DB15183
    Investigational

    Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).

  3. Drug

    Temelimab

    go.drugbank.com/drugs/DB15634
    Investigational

    Temelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).

  4. Drug

    Loracarbef

    go.drugbank.com/drugs/DB00447
    ApprovedWithdrawn

    Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

  5. Drug

    Ramiprilat

    go.drugbank.com/drugs/DB14208
    Experimental

    The active metabolite of the prodrug Ramipril.

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Rhodamine B

    go.drugbank.com/drugs/DB16853
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    AOD9604

    go.drugbank.com/drugs/DB06388
    Experimental

    AOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.

  8. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Currently dehydroascorbic acid is an experimental drug with no known approved indications. … Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans.

  9. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

  10. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.